Profile data is unavailable for this security.
About the company
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
- Revenue in USD (TTM)32.87m
- Net income in USD727.43m
- Incorporated2007
- Employees383.00
- LocationAgios Pharmaceuticals Inc88 Sidney StreetCAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 649-8600
- Fax+1 (302) 655-5049
- Websitehttps://www.agios.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scholar Rock Holding Corp | 0.00 | -225.97m | 2.80bn | 150.00 | -- | 38.14 | -- | -- | -2.36 | -2.36 | 0.00 | 0.9889 | 0.00 | -- | -- | 0.00 | -105.14 | -38.14 | -124.25 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.3875 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| Amicus Therapeutics, Inc. | 493.67m | -104.69m | 2.89bn | 517.00 | -- | 16.24 | -- | 5.85 | -0.3461 | -0.3461 | 1.63 | 0.5987 | 0.6367 | 0.5739 | 5.76 | 954,876.20 | -13.50 | -30.65 | -17.12 | -36.55 | 89.99 | 88.94 | -21.21 | -86.10 | 2.42 | 0.3214 | 0.6853 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| SpringWorks Therapeutics Inc | 135.49m | -275.16m | 2.90bn | 305.00 | -- | 5.51 | -- | 21.42 | -3.89 | -3.89 | 1.89 | 7.15 | 0.2517 | -- | -- | 444,219.70 | -51.12 | -36.97 | -57.59 | -39.49 | 94.52 | -- | -203.09 | -2,176.46 | 6.02 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| Kymera Therapeutics Inc | 87.56m | -167.47m | 2.91bn | 184.00 | -- | 3.41 | -- | 33.27 | -2.33 | -2.33 | 1.26 | 13.79 | 0.1103 | -- | 34.37 | 468,251.30 | -21.10 | -23.03 | -22.98 | -27.64 | -- | -- | -191.26 | -207.82 | -- | -- | 0.0035 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Dyne Therapeutics Inc | 0.00 | -294.51m | 3.02bn | 173.00 | -- | 4.25 | -- | -- | -3.56 | -3.56 | 0.00 | 6.93 | 0.00 | -- | -- | 0.00 | -60.47 | -52.81 | -65.37 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| Edgewise Therapeutics Inc | 0.00 | -124.29m | 3.05bn | 108.00 | -- | 6.18 | -- | -- | -1.49 | -1.49 | 0.00 | 5.18 | 0.00 | -- | -- | 0.00 | -30.22 | -- | -31.57 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Vera Therapeutics Inc | 0.00 | -134.38m | 3.06bn | 82.00 | -- | 9.00 | -- | -- | -2.60 | -2.60 | 0.00 | 5.25 | 0.00 | -- | -- | 0.00 | -49.39 | -- | -54.50 | -- | -- | -- | -- | -- | -- | -- | 0.1487 | -- | -- | -- | -7.79 | -- | -- | -- |
| Veracyte Inc | 425.33m | -9.27m | 3.07bn | 815.00 | -- | 2.71 | 214.95 | 7.21 | -0.1445 | -0.1445 | 5.61 | 15.18 | 0.3545 | 7.40 | 9.66 | 521,878.50 | -0.7723 | -6.33 | -0.8157 | -6.69 | 68.45 | 67.10 | -2.18 | -20.99 | 4.79 | -- | 0.00009 | -- | 21.76 | 31.45 | -103.51 | -- | 39.67 | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -213.39m | 3.14bn | 251.00 | -- | 3.96 | -- | -- | -2.81 | -2.81 | 0.00 | 10.53 | 0.00 | -- | -- | 0.00 | -28.32 | -20.71 | -29.38 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Agios Pharmaceuticals Inc | 32.87m | 727.43m | 3.18bn | 383.00 | 4.68 | 2.02 | 4.33 | 96.60 | 12.28 | 11.37 | 0.5778 | 28.53 | 0.0235 | 0.1598 | 15.31 | 85,825.06 | 51.98 | -29.54 | 55.50 | -31.88 | 89.38 | -- | 2,212.98 | -3,826.10 | 8.77 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| MoonLake Immunotherapeutics | 0.00 | -80.77m | 3.47bn | 50.00 | -- | 7.00 | -- | -- | -1.29 | -1.29 | 0.00 | 7.74 | 0.00 | -- | -- | 0.00 | -16.25 | -- | -18.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Denali Therapeutics Inc | 0.00 | -427.49m | 3.55bn | 390.00 | -- | 2.67 | -- | -- | -2.76 | -2.76 | 0.00 | 9.17 | 0.00 | -- | -- | 0.00 | -31.77 | -14.98 | -33.76 | -17.71 | -- | -- | -- | -104.50 | -- | -- | 0.0043 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Immunitybio Inc | 7.33m | -587.79m | 3.55bn | 672.00 | -- | -- | -- | 484.70 | -0.867 | -0.867 | 0.0108 | -1.07 | 0.0184 | -- | 1.53 | 11,675.16 | -147.53 | -112.76 | -182.67 | -316.07 | -- | -- | -8,018.00 | -37,700.74 | 2.64 | -2.19 | 4.22 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
Data as of Nov 25 2024. Currency figures normalised to Agios Pharmaceuticals Inc's reporting currency: US Dollar USD
57.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Farallon Capital Management LLCas of 30 Sep 2024 | 5.66m | 9.95% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 5.45m | 9.57% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 4.38m | 7.70% |
| Bellevue Asset Management AGas of 30 Sep 2024 | 3.74m | 6.57% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 2.77m | 4.88% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.33m | 4.10% |
| Armistice Capital LLCas of 30 Sep 2024 | 2.21m | 3.88% |
| Erste Asset Management GmbHas of 30 Sep 2024 | 2.18m | 3.84% |
| Erste Asset Management GmbH (Czech Republic)as of 30 Jun 2024 | 2.15m | 3.78% |
| Macquarie Investment Management Business Trustas of 30 Sep 2024 | 1.69m | 2.97% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
